Boston Scientific (BSX) Reaches $32.56 After 3.00% Up Move; Haemonetics (HAE) Had 4 Analysts Last Week

June 14, 2018 - By Migdalia James

Haemonetics Corporation (NYSE:HAE) Logo

Among 10 analysts covering Haemonetics Corporation (NYSE:HAE), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Haemonetics Corporation had 29 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Benchmark with “Hold” on Monday, November 7. JMP Securities upgraded the stock to “Market Outperform” rating in Thursday, July 13 report. The rating was maintained by Jefferies on Tuesday, June 20 with “Buy”. Morgan Stanley maintained Haemonetics Corporation (NYSE:HAE) rating on Wednesday, May 9. Morgan Stanley has “Overweight” rating and $100 target. On Tuesday, October 6 the stock rating was maintained by Barrington Research with “Outperform”. Barrington Research upgraded Haemonetics Corporation (NYSE:HAE) on Tuesday, August 8 to “Outperform” rating. The firm earned “Neutral” rating on Monday, August 15 by Sidoti. The rating was upgraded by Barrington Research on Tuesday, July 28 to “Outperform”. Morgan Stanley maintained the shares of HAE in report on Friday, October 6 with “Equal-Weight” rating. As per Thursday, November 9, the company rating was maintained by Morgan Stanley. See Haemonetics Corporation (NYSE:HAE) latest ratings:

09/05/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $77 New Target: $100 Maintain
28/03/2018 Broker: Morgan Stanley Rating: Buy Maintain
07/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $74 New Target: $77 Maintain
07/02/2018 Broker: Jefferies Rating: Buy New Target: $80.0 Maintain
08/01/2018 Broker: Jefferies Rating: Buy New Target: $75.0 Maintain
02/01/2018 Broker: Raymond James Old Rating: Underperform New Rating: Market Perform Upgrade
02/01/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Upgrade
21/12/2017 Broker: Jefferies Rating: Buy New Target: $68.0 Maintain

The stock of Boston Scientific Corporation (NYSE:BSX) is a huge mover today! The stock increased 2.63% or $0.83 during the last trading session, reaching $32.56. About 9.64 million shares traded or 20.62% up from the average. Boston Scientific Corporation (NYSE:BSX) has risen 11.19% since June 14, 2017 and is uptrending. It has underperformed by 1.38% the S&P500. Some Historical BSX News: ; 19/04/2018 – DJ Boston Scientific Corporation, Inst Holders, 1Q 2018 (BSX); 11/05/2018 – Boston Scientific Announces Real-World Data Demonstrating Success Of SMART Pass On The S-ICD System; 28/03/2018 – BOSTON SCIENTIFIC CORP SAYS BOSTON SCIENTIFIC PREVAILS IN U.K. EDWARDS LIFESCIENCES LITIGATION; 03/04/2018 – BOSTON SCIENTIFIC REPORTS PURCHASE OF SECURUS MEDICAL GROUP,; 16/05/2018 – Increasing Health-conscious and Sports Vision Treatments Impacting HealthCare Sector; 03/04/2018 – Boston Scientific Announces Acquisition Of Securus Medical Group, Inc; 26/04/2018 – BOSTON SCIENTIFIC CORP BSX.N : JP MORGAN RAISES TARGET PRICE TO $32 FROM $31; 25/04/2018 – BOSTON SCIENTIFIC CORP BSX.N FY2018 REV VIEW $9.75 BLN — THOMSON REUTERS l/B/E/S; 21/03/2018 – BOSTON SCIENTIFIC CORP – DEAL IS EXPECTED TO BE DILUTIVE ON A GAAP BASIS, DUE TO AMORTIZATION AND TRANSACTION AND INTEGRATION COSTS; 07/05/2018 – Boston Scientific To Participate In Bank of America Merrill Lynch 2018 Health Care ConferenceThe move comes after 7 months positive chart setup for the $44.93 billion company. It was reported on Jun, 14 by Barchart.com. We have $33.54 PT which if reached, will make NYSE:BSX worth $1.35 billion more.

Since January 2, 2018, it had 0 buys, and 9 insider sales for $1.14 million activity. 114 Haemonetics Corporation (NYSE:HAE) shares with value of $8,234 were sold by Scanlan Jacqueline. Basil Michelle L sold $28,097 worth of stock or 389 shares. Simon – Christopher sold 1,941 shares worth $179,989. 425 shares valued at $39,410 were sold by Burke William P. Mr. on Thursday, June 7. Ryding Neil Mr. also sold $16,970 worth of Haemonetics Corporation (NYSE:HAE) shares. Goldstein Dan sold $360,766 worth of stock or 3,794 shares. Shares for $448,434 were sold by KROLL MARK W.

The stock increased 4.88% or $4.48 during the last trading session, reaching $96.23. About 815,962 shares traded or 64.88% up from the average. Haemonetics Corporation (NYSE:HAE) has risen 121.77% since June 14, 2017 and is uptrending. It has outperformed by 109.20% the S&P500. Some Historical HAE News: ; 08/05/2018 – HAEMONETICS CORP – SEES FISCAL 2019 CASH FLOW FROM OPERATING ACTIVITIES (GAAP) $150 – $175 MLN; 08/05/2018 – Haemonetics 4th Quarter Fiscal 2018 Earnings Release Available on Investor Relations Website; 28/03/2018 – HAEMONETICS GETS FDA CLEARANCES FOR NEXSYS PCS SOFTWARE; 10/04/2018 – Haemonetics Sets Date for Publishing Fourth Quarter Fiscal 2018 Results: May 8, 2018; 08/05/2018 – HAEMONETICS SEES FY ’19 REV UP 3%-5%; 08/05/2018 – Haemonetics Sees FY19 EPS $1.50-EPS $1.80; 08/05/2018 – Haemonetics 4Q EPS 22c; 08/05/2018 – Haemonetics 4Q Rev $234M; 13/04/2018 – FDA: Acrodose PLus and PL Systems by Haemonetics: Recall – Low pH Readings for Platelets Stored in CLX HP Bag; 08/05/2018 – HAEMONETICS CORP – SEES FISCAL 2019 TOTAL REV GROWTH 3 PCT TO 5 PCT

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company has market cap of $5.02 billion. The firm operates through five divisions: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It has a 113.21 P/E ratio. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma clients to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.

Another recent and important Haemonetics Corporation (NYSE:HAE) news was published by Seekingalpha.com which published an article titled: “S&P indexes swap firms due to shifting market caps; FSB to SmallCap 600” on June 08, 2018.

Investors sentiment increased to 1.18 in Q1 2018. Its up 0.07, from 1.11 in 2017Q4. It improved, as 15 investors sold Haemonetics Corporation shares while 81 reduced holdings. 45 funds opened positions while 68 raised stakes. 49.88 million shares or 2.00% less from 50.89 million shares in 2017Q4 were reported. Columbus Circle Invsts holds 199,303 shares. Moreover, Citadel Advsr Ltd Liability Corp has 0% invested in Haemonetics Corporation (NYSE:HAE). New York-based Virtu Fincl Limited Co has invested 0.03% in Haemonetics Corporation (NYSE:HAE). Goldman Sachs Grp Inc Inc owns 165,013 shares or 0% of their US portfolio. National Bank & Trust Of America Corporation De reported 377,412 shares. Brinker invested 0.02% of its portfolio in Haemonetics Corporation (NYSE:HAE). Ser Automobile Association invested 0.02% in Haemonetics Corporation (NYSE:HAE). Cubist Systematic Strategies Ltd Co stated it has 0.01% in Haemonetics Corporation (NYSE:HAE). Barrow Hanley Mewhinney Strauss Ltd Llc reported 122,351 shares. Arizona State Retirement System holds 0.06% or 84,275 shares. Everence Mngmt, Indiana-based fund reported 3,650 shares. Fuller Thaler Asset Mngmt Inc reported 749,629 shares. 505,239 were reported by Geode Capital Mgmt Ltd Liability. Aqr Capital Management Ltd reported 0.01% of its portfolio in Haemonetics Corporation (NYSE:HAE). Jpmorgan Chase And stated it has 0.01% in Haemonetics Corporation (NYSE:HAE).

Since December 29, 2017, it had 0 buys, and 20 sales for $9.49 million activity. Pierce David A sold 5,152 shares worth $141,319. 42,803 shares were sold by Ballinger Kevin J., worth $1.21M. The insider Sorenson John Bradley sold $381,949. 15,835 Boston Scientific Corporation (NYSE:BSX) shares with value of $399,865 were sold by Phalen Michael P.. Shares for $225,413 were sold by Butcher Arthur C. Shares for $603,368 were sold by Thepaut Eric Francis Yves. $2.26M worth of stock was sold by Fitzgerald Joseph Michael on Wednesday, February 7.

Boston Scientific Corporation develops, makes, and markets medical devices for use in various interventional medical specialties worldwide. The company has market cap of $44.93 billion. It operates through three divisions: Cardiovascular, Rhythm Management, and MedSurg. It has a 428.49 P/E ratio. The firm offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; other coronary therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Among 33 analysts covering Boston Scientific Corporation (NYSE:BSX), 27 have Buy rating, 0 Sell and 6 Hold. Therefore 82% are positive. Boston Scientific Corporation has $36 highest and $19 lowest target. $30.61’s average target is -5.99% below currents $32.56 stock price. Boston Scientific Corporation had 101 analyst reports since July 27, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Buy” rating and $32.0 target in Thursday, February 1 report. The stock has “Buy” rating by Nomura on Thursday, March 17. The stock of Boston Scientific Corporation (NYSE:BSX) has “Buy” rating given on Friday, September 1 by RBC Capital Markets. Cowen & Co maintained Boston Scientific Corporation (NYSE:BSX) on Thursday, July 27 with “Buy” rating. The firm has “Buy” rating by Needham given on Wednesday, June 28. As per Tuesday, October 31, the company rating was maintained by SunTrust. The firm has “Overweight” rating by JP Morgan given on Thursday, April 26. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Buy” rating by Bank of America on Thursday, April 5. Oppenheimer maintained it with “Hold” rating and $27 target in Monday, May 1 report. The company was maintained on Wednesday, November 29 by Canaccord Genuity.

More notable recent Boston Scientific Corporation (NYSE:BSX) news were published by: Seekingalpha.com which released: “Boston Scientific Is A Good Earnings Story – Cramer’s Lightning Round (6/13/18)” on June 14, 2018, also Benzinga.com with their article: “Boston Scientific Halted On Stryker Takeover Approach” published on June 11, 2018, Streetinsider.com published: “Stryker (SYK) is not in discussions with Boston Scientific (BSX)” on June 13, 2018. More interesting news about Boston Scientific Corporation (NYSE:BSX) were released by: Streetinsider.com and their article: “Stryker (SYK) Made Takeover Approach for Boston Scientific (BSX) – WSJ” published on June 11, 2018 as well as Benzinga.com‘s news article titled: “Benzinga Pro’s 5 Stocks To Watch Today” with publication date: June 12, 2018.

Haemonetics Corporation (NYSE:HAE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Migdalia James

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: